BioGaia ABBGLAF 100 Days Inventory is 144.19 as of Mar. 2026, which is 7% above its 10-year median of 135.36. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 916 Drug Manufacturers companies, BioGaia AB ranks better than 60.37% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). BioGaia AB's Average Total Inventories for the
three
months ended in Mar. 2026 was $17.9 Mil. BioGaia AB's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $11.4 Mil.
Hence, BioGaia AB's Days Inventory for the
three
months ended in Mar. 2026 was 144.19.
The historical rank and industry rank for BioGaia AB's Days Inventory or its related term are showing as below:
BGLAF'
s Days Inventory Range Over the Past 10 Years
Min: 75.4 Med: 135.36 Max: 170.76
Current: 139.72
During the past 13 years, BioGaia AB's highest Days Inventory was 170.76. The lowest was 75.40. And the median was 135.36.
BGLAF's Days Inventory is ranked better than 60.37% of 916
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs BGLAF: 139.72
BioGaia AB's Days Inventory
increased
from Mar. 2025 (131.46) to Mar. 2026 (144.19).
It might indicate that BioGaia AB's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioGaia AB's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.63.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioGaia AB's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.45.
BioGaia AB (OTCPK:BGLAF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BioGaia AB's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioGaia AB's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BioGaia AB Days Inventory Related Terms
BioGaia AB Days Inventory Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Days Inventory of 144.19 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioGaia AB and its competitors. This is near median its historical median of 135.36. Over the past decade, BioGaia AB's Days Inventory has ranged from 75.40 to 170.76. According to the industry distribution chart, BioGaia AB ranks #363 out of 916 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is BioGaia AB's Days Inventory too high?
BioGaia AB's current Days Inventory of 144.19 is near median its 10-year median of 135.36. Over the past 10 years, this metric has ranged from a low of 75.40 to a high of 170.76. The Drug Manufacturers industry median Days Inventory is 164.43. BioGaia AB's value of 144.19 is 12.3% below this industry median. Based on the distribution chart, BioGaia AB ranks #363 out of 916 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #363 out of 916 companies for Days Inventory. This puts BioGaia AB in the upper half of its industry. The industry median Days Inventory is 164.43. BioGaia AB's value of 144.19 is 12.3% below this benchmark. Historically, BioGaia AB's own Days Inventory has ranged from 75.40 to 170.76 over the past decade. While the company's 10-year median is 135.36 vs. the industry median of 164.43, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 916 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Days Inventory of 144.19 is 12.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Days Inventory is 144.19, which is near median its own 10-year median of 135.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Days Inventory of 144.19. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Days Inventory is 144.19, which is near median its 10-year median of 135.36 and 12.3% below the Drug Manufacturers industry median of 164.43. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Days Inventory is 144.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Days Inventory: 144.19 (near median its 10-year median of 135.36)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 12.3% below the Drug Manufacturers median (#363 of 916)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
